AC Immune Company
AC Immune is a Swiss biopharmaceutical company that focuses on developing therapeutic and diagnostic products for neurodegenerative diseases caused by misfolding proteins. They have three product candidates in clinical trials and two proprietary technology platforms that create antibodies, small molecules, and vaccines for a broad range of neurodegenerative indications. AC Immune is a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Total Funding:
117439497
Headquarters:
Lausanne, Vaud
Funding Status:
IPO
Employee Number:
51-100
Estimated Revenue:
$10M to $50M
Last Funding Type:
Series E
Technology:
Therapeutic and Diagnostics
Last Funding Date:
09 05 16
Investors Number:
2
Founded Date:
2003
Industry:
BioTech